TASQUINIMOD + Ruxolitinib for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Mar 2024: Trial registered, NCT06327100
  2. 1 Aug 2024: Trial started, NCT06327100

The trials

NCT06327100: Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

State
Under way
Phase
Phase 1 and Phase 2
People
33 planned
Started
1 Aug 2024
Primary completion
1 May 2029
Arms
Group 2
Results
None posted
  1. 25 Mar 2024: Trial registered
  2. 1 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.